Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Down to $13.56

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report)'s stock price gapped down prior to trading on Monday . The stock had previously closed at $13.56, but opened at $11.08. Neumora Therapeutics shares last traded at $11.39, with a volume of 381,439 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. JPMorgan Chase & Co. upped their target price on shares of Neumora Therapeutics from $20.00 to $22.00 and gave the company an "overweight" rating in a report on Monday, March 18th. William Blair reaffirmed an "outperform" rating on shares of Neumora Therapeutics in a report on Friday. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $31.00 price target on shares of Neumora Therapeutics in a research note on Thursday, March 28th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $22.57.

Neumora Therapeutics Trading Down 17.5 %

The firm's 50-day simple moving average is $16.06 and its two-hundred day simple moving average is $14.22.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last issued its earnings results on Thursday, March 7th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.05. Equities analysts anticipate that Neumora Therapeutics, Inc. will post -1.48 EPS for the current fiscal year.

Institutional Trading of Neumora Therapeutics

Several large investors have recently modified their holdings of the business. Amalgamated Bank purchased a new position in shares of Neumora Therapeutics during the fourth quarter valued at approximately $29,000. California State Teachers Retirement System purchased a new position in Neumora Therapeutics during the fourth quarter worth approximately $42,000. Tower Research Capital LLC TRC purchased a new position in Neumora Therapeutics during the fourth quarter worth approximately $44,000. Strs Ohio purchased a new position in Neumora Therapeutics during the fourth quarter worth approximately $54,000. Finally, SG Americas Securities LLC purchased a new position in Neumora Therapeutics during the fourth quarter worth approximately $108,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.